Leadership Transition at ADMA Biologics

ADMA Biologics, Inc. (Nasdaq: ADMA), a leading end-to-end commercial biopharmaceutical entity, disclosed a significant leadership change today. Brian Lenz, who currently serves as Executive Vice President, Chief Financial Officer & General Manager of ADMA BioCenters, will be transitioning from these roles to a consulting capacity, effective April 1, 2024.

In light of Lenz’s transition, Adam Grossman, President and Chief Executive Officer of ADMA, will assume the role of Interim Chief Financial Officer, effective April 1, 2024. Additionally, the company has commenced an executive search for a permanent Chief Financial Officer.

Adam Grossman expressed appreciation on behalf of the company’s Board of Directors for Lenz’s extensive contributions. Grossman highlighted Lenz’s pivotal role in ADMA’s journey, spanning from its initial public offering over a decade ago to his instrumental involvement in driving expansion, growth, and corporate profitability. Lenz’s tenure also saw the successful execution of multiple financing endeavors and the expansion of ADMA’s BioCenters business unit. Grossman conveyed best wishes to Lenz and emphasized the continuation of collaboration during the transition phase.

Reflecting on his 11-year tenure as CFO, Brian Lenz expressed deep gratitude and pride in the company’s evolution from a startup biotech firm to a profitable biopharmaceutical entity with three FDA-approved products catering to patients in critical need. Lenz conveyed his best wishes to the ADMA team as they embark on a promising future.

Have you read?
Ranking the 50 greatest revenge movies of all time.
Ranked: The World’s Most Powerful Countries For 2023.
Ranked: Countries with the highest share of women in parliament.
The World’s Largest old Producing Countries, 2023.
Ranked: The World’s Most Influential Countries, 2023.
Ranked: World’s Most Forward-Thinking Countries, 2023.